Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-06-05
2007-06-05
Rawlings, Stephen L. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007200, C435S330000, C530S350000, C530S387100, C530S387700, C530S388800, C530S389700, C530S391300, C436S064000
Reexamination Certificate
active
10049608
ABSTRACT:
The present invention is directed to cell surface antigenes found on myeloma cells and on ovarian cancer cells that are recognized by monoclonal antibodies, and antibody binding fragments thereof, as described. The monoclonal antibodies of the invention are capable of being used for therapeutic, screening, diagnostic and cell purification purposes. A representative and exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to a surface antigen that is expressed on multiple myeloma cells and to a surface antigen that is expressed on ovarian cancer cells. The function of this monoclonal antibody both in vivo and in vitro is demonstrated.
REFERENCES:
patent: 88/03954 (1988-06-01), None
patent: 94/05329 (1994-03-01), None
patent: 96/26964 (1996-09-01), None
patent: 96/40295 (1996-12-01), None
patent: WO 01/012674 (2001-02-01), None
Krueger et al. (J. Immunother. Jul.-Aug. 2001; 24 (4): 334-344).
Krueger et al. (Cancer Immunother. Jun. 2003; 52 (6): 367-377).
De Plaen et al. (Immunogenetics. 1994; 40: 360-369).
Skolnick et al. (Trends in Biotechnology. 2000; 18 (1): 34-39).
Partington K.M. et al.: “A Novel Method Of Cell Separation Based On Dual Parameter Immunomagnetic Cell Selection” Journal of Immunological Methods, NL, Elsevier Science Publishers B.V., Amsterdam; vol. 223, No. 2; Mar. 4, 1999 pp. 195-205.
Ozaki S. et al.: “Immunotherapy Of Multiple Myeloma With A Monoclonal Antibody Directed Against A Plasma Cell-Specific Antigen, HM1.24” Blood, W.B. Saunders, Philadelphia, VA, US; vol. 90, No. 8; Oct. 15, 1997.
Tai Y -T et al.: “Isolation And Characterization Of Human Multiple Myeloma Cell Enriched Populations” Journal of Immunological Methods, NL, Elsevier Science Publsihers B.V., Amsterdam; vol. 235, No. 1-2; Feb. 2000; pp. 11-19.
D. Avichezer et al., 1977, “Immunoreactivities of Polyclonal and Monoclonal Anti-T and Anti-Tn Antibodies with Human Carcinoma Cells, GrownIn Vitroand in a Zenograft Model”,Int. J. Cancer, 72:119-127.
S. Miotti et al., 1999 “Level of Anti-Mouse-Antibody Response Induces by Bi-Specific Monoclonal Antibody OC/TR in Ovarian-Carcinoma Patietns is Associated with Longer Survival”.Int. J. Cancer, 84-62-68.
J. A. Francisco et al., 1997, “In Vivo Efficacy and Toxicity of a Single-Chain Immunotoxin Targeted to CD40”,Blood, 89:4493-4500.
C.F.M. Molthoff et al., 1997, “Escalating Protein Doses of Chimeric Monoclonal Antibody Mov18 Immunoglobulin G. In Ovarian Carcinoma Patients: A Phase 1 Study”.Cancer Supplement. 80:2712-2720.
E. Kievit et al., 1997, “Determination of Tumor-Related Factors of Influence on the Uptake of the Monoclonal Antibody 323/A3 in Experimental Human Ovarian Cancer”,Int. J. Cancer, 71:237-245.
K.O. Lloyd et al., 1997, “Isolation and Characterization of Ovarian Cancer Antigen CA 125 using a New Monoclonal Antibody (VK-8): Identification as a Mucin-Type Molecule”,Int. J. Cancer, 71:842-580.
A. van dalen, 1999, “BR-MA, OM-MA, GI-MA and CEA: Clinical Evaluation Using the Immulite Analyzer”,Tumore Biology, 20:117-129.
G. Gebauer et al., 1999, “IMMULITE ® OM-MA Assay: A Useful Diagnostic Tool in Patients with Bemgn and Malignant Ovarian Tumors”,Anticancer Research, 19:2535-2536.
S.P. Treon et al., 1999, “Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induces by Dexamethasone”.Blood, 93:1287-1298.
K. Ono et al., 1999, “The humanized anit-HM1.24 antibody effectively kills multiple myeolma cells by human effector cell-mediated cytotoxicity”,Mol. Immunology, 36:387-395.
G. Teoh et al., 1998, “The 86kD Subunit of Ku Autoantigen Mediates Homotypic and Heterotypic Adhesion of Multiple Myeloma Cells”.J. Clin. Invest. 101:1379-1388.
W.C.A.M. Buijs et al., 1998, “Dosimetric analysis of chimeric monclonal antibody cMOv 18 IgG in ovarian carcinoma patients after intraperitoneal and intravenouse administration”.Eur. J. Nuclear Medicine. 25:1552-1561.
M.A. Bookman, 1998, Biological Therapy of Ovarian Cancer; Current Directions:.Seminars in Oncology, 25:381-396.
M. Kawata et al., 1998, “Detection of Epithelial Ovarian-Cancer-Associated Antigens Involved in Immune Complexes by Monoclonal Antibodies”,Tumor Biology, 19:1-11.
S.A. McQuarrie et al., 1997, “Pharmacokinetics and radiation dosimetry of9Tcm-labelled monoclonal antibody B43.13 in ovarian cancer patients”,Nuclear Medicine Communications. 18:878-886.
E. Kievit et al., 1997. “Comparison of the Biodistribution and the Efficacy of Monoclonal Antibody 323/A3 Labeled with Either131I or186Re in Human Ovarian Cancer Zenografts”,Int. J. Radiation Oncology bio. Phys., 38:813-832.
M. Hartman et al., 1999, “MUCI Isoform Specific Monoclonal Antibody 6E6/2 Detects Preferential Expression of the Novel MUCI/Y Protein in Breast and Ovarian Cancer”,Int. J. Cancer, 82-256-267.
M.L. Grossbard et al., 1998 “Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma”,British Journal of Haematology, 102:509-515.
H Bertz et al., 1997. “Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect”,Leukemia. 11:281-283.
J L. Hornick et al . 1997, “Chimeric CLL-1 antibody Fusion Proteins Containing Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2 with Specificity for B-Cell Malignancies Exhibit Enhanced Effector functions while Retaining Tumor Targeting Properties”,Blood, 89:4437-4447.
D G. Maloney et al., 1999, “Antibody Therapy for treatment of Multiple Myeloma”.Seminars in Hematology(Suppl.), 36:30-33.
V Nuessler et al., 1997, “Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease”Leukemia(Suppl.), 11:S10-S14.
G.J. Ossenkoppele, 1997, “Treatment of Multiple Myeloma in Elderly Patients”,Drugs&Aging, 11:152-164.
T.H. Totterman et al., 1998, “Targeted Superantigens for Immunotherapy of Haematopoietic Tumors”,Vox Sanguinis, 74:483-487.
M.G. Rosenblum et al., 1999, “Phase 1 Study of90Y-labeled B72.3 Intraperitoneal Administration in Patients with Ovarian Cancer: Effect of Dose and EDTA Coadministration on Pharmacokinetics and Toxicity”,Clinical Cancer Research, 5:953-961.
R.H. M. Verheijen et al., 1999, “CA 125: fundamental and clinical aspects”,Seminars in Cancer Biology, 9:117-124.
G. Fleckenstein et al., 1998, “Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer”,Medical Oncology, 15:212-221.
E. Kievit et al., 1998 “[186Re]-Labeled Mouse and Chimeric Monoclonal Antibody 323/A3: a Comparison of the Efficacy in Experimental Human Ovarian Cancer”,Nuclear Medicine&Biology, 25:37-45.
S. Nicholson et al., 1998, “Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: A matched analysis”,Oncology Reports, 5:223-226.
B C. Schultes et al., 1998, Anti-idiotype induction therapy: anti-CA125 antiodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).Cancer Immunol. Immunother. 46:201-212.
M. Jojovic et al., 1998, “Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe combined immunodeficient mice”,Histochemical Journal, 30:723-729.
C. Kosmas et al., 1998, “Monoclonal Antibody Targeting of Ovarian Carcinoma”,Oncology, 55:435-446.
M.F. Federici et al., 1999. “Selection of Carbohydrate Antigens in Human Epithelial Ovarian Cancers as Targets for Immunotherapy: Serous and Mucinous Tumors Exhibit Distinctive Patterns of Expression”,Int
Molecular Discoveries, Inc.
Morgan & Finnegan , LLP
Rawlings Stephen L.
LandOfFree
Ovarian cancer cell and myeloma cell surface glycoproteins,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ovarian cancer cell and myeloma cell surface glycoproteins,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ovarian cancer cell and myeloma cell surface glycoproteins,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3873164